Kyntra Bio
Nasdaq KYNB · San Francisco, CA
Works in Genetic & rare · GI & liver · Hematology · Infectious disease · Metabolic & endocrine · Musculoskeletal · Neurology · Oncology · Renal & urogenital · Respiratory · Women's health
Kyntra Bio is a clinical trial sponsor based in San Francisco, CA, listed as Nasdaq KYNB. It has 2 active clinical trials with 276 planned participants, across 11 therapeutic areas. Since 2021 it has completed 17 trials and stopped 8 early.
Trial track record · since 2021
Financials · Nasdaq KYNB
Pipeline · 2 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Kyntra Bio
Kyntra Bio is lead sponsor of 2 active clinical trials on ClinicalTrials.gov, with 276 planned participants, in Genetic & rare, GI & liver, Hematology, Infectious disease and other areas. Since 2021 it has completed 17 trials and stopped 8 early.
Kyntra Bio is based in San Francisco, CA and is listed as Nasdaq KYNB. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Kyntra Bio; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-08-17.
Approve Suite is not affiliated with Kyntra Bio.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.